Extracorporeal carbon dioxide removal (ECCO<sub>2</sub>R) in patients with acute respiratory failure.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28132075.
- Also identified by DOI 10.1007/s00134-016-4673-0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To review the available knowledge related to the use of ECCO<sub>2</sub>R as adjuvant strategy to mechanical ventilation (MV) in various clinical settings of acute respiratory failure (ARF). Expert opinion and review of the literature. ECCO<sub>2</sub>R may be a promising adjuvant therapeutic strategy for the management of patients with severe exacerbations of COPD and for the achievement of protective or ultra-protective ventilation in patients with ARDS without life-threatening hypoxemia. Given the observational nature of most of the available clinical data and differences in technical features and performances of current devices, the balance of risks and benefits for or against ECCO<sub>2</sub>R in such patient populations remains unclear CONCLUSIONS: ECCO<sub>2</sub>R is currently an experimental technique rather than an accepted therapeutic strategy in ARF-its safety and efficacy require confirmation in clinical trials.
Medical subject headings
- Carbon Dioxide
- Extracorporeal Circulation
- Hypercapnia
- Respiration, Artificial
- Respiratory Distress Syndrome
- Ventilator-Induced Lung Injury